Diagnostic Interval for Oldest-Old Patients with II–III Stage Right Colon Cancer

Introduction: the lack of comprehensive screening programs for colorectal cancer detection in oldest-old steadily leads to an increase in the diagnostic interval (DI), i.e. the time from the patient’s first presentation of complaints until diagnosis and treatment. At the same time, worsening the general somatic condition and developing the decompensation of concomitant diseases. Thus, patients with long-term DI need additional measures while preparing for surgery; the preoperative bed-day increases.

Purpose of the study: to evaluate the impact of the diagnostic interval on the short-term results of II and III stages right colon cancer treatment in geriatric patients.

Materials and methods: a retrospective multicenter study was conducted at the surgical facilities of Sechenov University from 2006 to 2015. The study included patients aged over 75 who have undergone surgical treatment of II and III stages right colon cancer. The control group comprised patients with CRC diagnosis in the period from 0 to 6 months; the studied group involved patients with a diagnostic interval over than 6 months.

Results and conclusions. Analysis of the results revealed that patients older than 80 years had a longer diagnostic interval, which is statistically significant (p<0.001). Prolongation of the diagnostic interval for more than 6 months has shown a decrement in the polymorbidity indicators and operational and anesthetic risk compared with DI≤6 months (p=0.001, p=0.039). Polymorbidity, in particular cardiovascular diseases decompensation, affected the indicators of operational and anesthetic risk on the ASA scale, which were significantly higher in the study group (p=0.039). High level of polymorbidity required a longer preoperative preparation in the studied group, which is statistically significant in comparison with the control group (p=0.018). Statistically significant differences in early postoperative complications rate in both groups were not revealed. 30 and 90 day mortality rates were similar in the studied and control groups (p=0.225, p=0.353). The study has also shown that diagnostic interval (DI) have no effect on the prevalence of II and III stages comparing with the control group (p=0.315).

1. http://www.demoscope.ru/weekly/2019/0829/barom05.php#_ftn21

2. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние Онкологической Помощи Населению России В 2017 Году. М.: МНИОИ Им. П.А. Герцена Филиал ФГБУ «НМИЦ Радиологии» Минздрава России, 2018. Илл. — 236 с. ISBN 978- 5-85502-237-7: 2018.

3. Wolf A.M.D., Fontham E.T.H., Church T.R., Flowers C.R., Guerra C.E., LaMonte S.J., et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin 2018; 68: 250–81. https://doi.org/10.3322/CAAC.21457

4. Schuld J., Glanemann M. Chirurgische Therapie des kolorektalen Karzinoms im Alter. Chirurg. 2017; 88: 123–30. https://doi.org/10.1007/s00104-016-0342-7

5. Davidson K.W., Barry M.J., Mangione C.M., Cabana M., Caughey A.B., Davis E.M., et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA — J Am Med Assoc 2021; 325: 1965–77. https://doi.org/10.1001/JAMA.2021.6238

6. Bibbins-Domingo K., Grossman D.C., Curry S.J., Davidson K.W., Epling J.W., García F.A.R., et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA — J Am Med Assoc 2016; 315: 2564–75. https://doi.org/10.1001/jama.2016.5989

7. Karsa L. Von, Patnick J., Segnan N. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition Executive summary. Endoscopy 2012; 44. https://doi.org/10.1055/s-0032-1309822

8. Приказ Министерства здравоохранения РФ от 26 ок- тября 2017 г. № 869н «Об утверждении порядка проведения диспансеризации определенных групп взрослого населения» https://www.garant.ru/products/ipo/prime/doc/71730314/

9. Polyanskaya E.A., Fedyanin M.Y., Tryakin A.A., Tjulandin S.A. Colorectal cancer, screening: achievements и opportunities. Color Oncol 2018; 8: 11–29. https://doi.org/10.17650/2220-3478-2018-8-4-11-29

10. Последние статистические данные по раку: [Регистр / статистика Национального центра исследований рака] https://ganjoho.jp/reg_stat/statistics/stat/summary.html

11. Lee Y.H., Kung P.T., Wang Y.H., Kuo W.Y., Kao S.L., Tsai W.C. Effect of length of time from diagnosis to treatment on colorectal cancer survival: A population-based study. PLoS One 2019; 14. https://doi.org/10.1371/JOURNAL.PONE.0210465

12. Iversen L.H., Antonsen S., Laurberg S., Lautrup M.D. Therapeutic delay reduces survival of rectal cancer but not of colonic cancer. Br J Surg 2009; 96: 1183–9. https://doi.org/10.1002/bjs.6700

13. Wattacheril J., Kramer J.R., Richardson P., Havemann B.D., Green L.K., Le A., et al. Lagtimes in diagnosis and treatment of colorectal cancer: Determinants and association with cancer stage and survival. Aliment Pharmacol Ther 2008; 28: 1166–74. https://doi.org/10.1111/j.1365-2036.2008.03826.x

14. Helewa R.M., Turner D., Park J., Wirtzfeld D., Czaykowski P., Hochman D., et al. Longer waiting times for patients undergoing colorectal cancer surgery are not associated with decreased survival. J Surg Oncol 2013; 108: 378–84. https://doi.org/10.1002/jso.23412